Zoetis stock analysis
Zoetis (1ZTS) Stock Price & Analysis
1ZTS Stock Chart & Stats
- Day’s Range
- EUR 72.50 - EUR 74.00
- 52-Week Range
- EUR 52.00 - EUR 161.00
- Previous Close
- EUR 71.52
- Volume
- N/A
- Average Volume (3M)
- 346
- Market Cap
- EUR 30.00B
- Enterprise Value
- EUR 36.45B
- Total Cash (Recent Filing)
- EUR 1.53B
- Total Debt (Recent Filing)
- EUR 9.24B
- Price to Earnings (P/E)
- 14.0
- Beta
- 0.27
- Next Earnings
- Feb 16, 2027 (Est.)
- EPS Estimate
- 1.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.62%
Bulls Say, Bears Say
Bulls Say
High Profitability And Cash Generation
Zoetis combines high margins with substantial operating and free cash flow, indicating that earnings are strongly cash-backed. This financial capacity supports research, commercial investment, dividends, and repurchases while helping the company sustain its competitive position through normal market cycles.
Diversified Animal Health Portfolio
Growth across livestock, international markets, and diagnostics provides meaningful diversification beyond pressured U.S. companion-animal products. This breadth can reduce dependence on any single franchise, support recurring customer relationships, and create multiple avenues for durable expansion.
Pipeline And Product Innovation
The planned launches and broader pipeline provide potential lifecycle extensions and new growth categories in animal health. Although contribution is expected to build gradually, continued approvals and innovation can refresh established franchises and support longer-term revenue durability.
Bears Say
Companion Animal And Dermatology Pressure
Companion-animal weakness, especially dermatology competition and Apoquel share loss, is affecting a strategically important product area. Persistent pressure could restrain revenue and earnings growth until newer products scale and the company stabilizes market share.
High Financial Leverage
Debt materially exceeds the equity base, reducing balance-sheet flexibility relative to the company’s otherwise strong profitability. If growth remains soft or financing costs stay elevated, leverage could constrain investment choices and increase sensitivity to weaker operating performance.
Demand And Margin Headwinds
Recent revenue contraction and lower margins indicate that demand, product mix, and competitive pricing are pressuring near-term earnings quality. Continued clinic-visit weakness and affordability concerns could prolong these headwinds before pipeline launches materially contribute.
Zoetis News
1ZTS FAQ
What was Zoetis’s price range in the past 12 months?
What is Zoetis’s market cap?
When is Zoetis’s upcoming earnings report date?
How were Zoetis’s earnings last quarter?
Is Zoetis overvalued?
Does Zoetis pay dividends?
What is Zoetis’s EPS estimate?
How many shares outstanding does Zoetis have?
What happened to Zoetis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zoetis?
What is the TipRanks Smart Score and how is it calculated?
Zoetis Stock Smart Score
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Website
- www.zoetis.com
- Address
- 10 Sylvan Way, Parsippany, NJ, 07054, US
Zoetis (1ZTS) Earnings & Revenues
1ZTS Company Deck
1ZTS Earnings Call
Earnings Call SentimentNeutral
The call reflected a mixed outlook. Zoetis demonstrated resilience through livestock growth, diagnostics momentum, portfolio diversity, promotional share defense, raised earnings guidance, and continued pipeline progress. However, near-term performance remained pressured by declines in companion animal revenue, dermatology competition, generic erosion, softer clinic visits, affordability concerns, lower gross margin, and cautious 2027 assumptions. The positive execution and longer-term innovation opportunities were balanced by significant current-market challenges.
View all IT:1ZTS earnings summaries1ZTS Net sales Breakdown
- 20.69% Vaccines
- 24.73% Parasiticides
- 18.53% Dermatology
- 10.94% Anti-infectives
- 8.87% Pain and sedation
- 7.36% Other pharmaceuticals
- 4.58% Animal health diagnostics
- 2.78% Other non-pharmaceuticals
- 0.29% Medicated feed additives
- 1.23% Contract manufacturing & human health
1ZTS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 6 | 7 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 6 | 0 | 6 |
